Mehran F. Moghaddam, PhD, MBA, obtained his doctorate in medicinal chemistry at Oregon State University-School of Pharmacy and completed his postdoctoral training in lipid metabolism at University of California-Davis. He also completed his executive MBA program at University of Southern California-Marshall School of Business.
Dr. Moghaddam’s industrial career started by joining DuPont in 1995, followed by Pfizer in 2001, and Celgene in 2003. While his efforts in DuPont and Pfizer were for most-part focused on the development of small molecules, his 13+ years in Celgene were dedicated to discovery and characterization of both small molecules and biologics. From 2009-2017, he served as the head of Discovery Drug Metabolism and Pharmacokinetics (DMPK) in Celgene Corporation. Recently, Dr. Moghaddam founded OROX BioSciences, Inc., dedicated to efficient and accelerated discovery of pharmaceuticals primarily for treatment of fibrotic ailments.
Dr. Moghaddam has been a co-inventor on more than 5 patents. He has authored/co-authored nearly 50 publications on a variety of subject matters. He is a section editor for Current Medicinal Chemistry and a reviewer on numerous peer-reviewed scientific journals. Also, he is on the editorial board of Drug Metabolism Letters and DARU. Additionally, he has served as session chair and co-organizer in several conferences.